Genetic Mutations in Gastric Cancer for Personalized Medicine
Author Information
Author(s): Joanna D Holbrook, Joel S Parker, Kathleen T Gallagher, Wendy S Halsey, Ashley M Hughes, Victor J Weigman, Peter F Lebowitz, Rakesh Kumar
Primary Institution: Glaxosmithkline R&D
Hypothesis
Can genetic characterization of gastric adenocarcinoma samples identify mutations relevant for targeted therapies?
Conclusion
Targeted therapies could benefit approximately 22% of gastric cancer patients studied, with novel mutations suggesting new drug targets.
Supporting Evidence
- Genetic alterations were found in key cancer pathways.
- 22% of patients may benefit from existing targeted therapies.
- Novel mutations could lead to new drug targets.
Takeaway
Doctors looked at the genes of stomach cancer samples to find changes that could help choose better treatments for patients.
Methodology
The study used SNP arrays, mRNA expression arrays, and deep sequencing of 384 genes in 50 gastric adenocarcinoma samples.
Potential Biases
Potential bias from the selection of samples and the reliance on specific sequencing technologies.
Limitations
The study's findings may not apply to all gastric cancer patients due to the heterogeneous nature of the disease.
Participant Demographics
Samples were obtained from hospitals in Russia and Vietnam.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website